Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Andrew R. Greenspan

Oncology | Hematology
Indiana University Health Inc
1030 W Michigan St, 
Indianapolis, IN 
Accepting New Patients

Advanced in WT1-Related Wilms Tumor Syndromes
Indiana University Health Inc
1030 W Michigan St, 
Indianapolis, IN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Andrew Greenspan is an Oncologist and a Hematologist in Indianapolis, Indiana. Dr. Greenspan is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Familial Colorectal Cancer, Gastroesophageal Junction Cancer, Paget Disease of the Breast, and Colorectal Cancer. Dr. Greenspan is currently accepting new patients.

His clinical research consists of participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in IN
Hospital Affiliations
Indiana University Health Bloomington Hospital
Indiana University Health
Indiana University Health Tipton Hospital Inc
Iu Health West Hospital
Indiana University Health North Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Zing Health
  • MEDICARE MAPD
  • MEDICARE SNP
View 17 Less Insurance Carriers -

Locations

INDIANA UNIVERSITY HEALTH INC
1030 W Michigan St, Indianapolis, IN 46202
Call: 317-944-4243
Other Locations
INDIANA UNIVERSITY HEALTH INC
6845 Rama Dr, Indianapolis, IN 46219
Call: 317-962-9000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


6 Clinical Trials

Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188
Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188
Enrollment Status: Completed
Publish Date: March 18, 2025
Intervention Type: Drug, Procedure
Study Drugs: Pembrolizumab, Gemcitabine, Cisplatin
Study Phase: Phase 1/Phase 2
A Phase I/Ib, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination With Vorinostat in Patients With Advanced Renal or Urothelial Cell Carcinoma
A Phase I/Ib, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination With Vorinostat in Patients With Advanced Renal or Urothelial Cell Carcinoma
Enrollment Status: Completed
Publish Date: November 18, 2024
Intervention Type: Drug
Study Drugs: Pembrolizumab, Vorinostat
Study Phase: Phase 1
A Randomized Phase II Trial to Evaluate the Efficacy of Supportive Therapy With Ginseng for Patients on Treatment With Regorafenib
A Randomized Phase II Trial to Evaluate the Efficacy of Supportive Therapy With Ginseng for Patients on Treatment With Regorafenib
Enrollment Status: Terminated
Publish Date: June 26, 2024
Intervention Type: Dietary supplement, Drug
Study Phase: Phase 2
A Phase I/II Study of Carboplatin/Nab-Paclitaxel and Pembrolizumab for Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Phase I/II Study of Carboplatin/Nab-Paclitaxel and Pembrolizumab for Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: May 23, 2023
Intervention Type: Drug
Study Drugs: Carboplatin, Nab-paclitaxel, MK-3475
Study Phase: Phase 1/Phase 2
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170
Enrollment Status: Terminated
Publish Date: July 11, 2022
Intervention Type: Drug, Radiation
Study Phase: Phase 2
Randomized Phase II Trial of Single Agent Chemotherapy Plus Nivolumab or Single Agent Chemotherapy Alone in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
Randomized Phase II Trial of Single Agent Chemotherapy Plus Nivolumab or Single Agent Chemotherapy Alone in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
Enrollment Status: Terminated
Publish Date: July 11, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Theodore Logan
Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Theodore Logan
Hematology | Oncology

Iu Health Medical Group LLC

1701 N Senate Blvd, 
Indianapolis, IN 
 (1.3 miles away)
888-484-3258
Languages Spoken:
English
See accepted insurances

Theodore Logan is a Hematologist and an Oncologist in Indianapolis, Indiana. Dr. Logan is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Melanoma, Clear Cell Sarcoma, and WT1-Related Wilms Tumor Syndromes.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Nabil Adra
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Nabil Adra
Hematology Oncology | Hematology | Oncology

University Medical Diagnostic Associates Inc

535 Barnhill Dr, 
Indianapolis, IN 
 (0.1 miles away)
317-274-8660
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nabil Adra is a Hematologist Oncology specialist and a Hematologist in Indianapolis, Indiana. Dr. Adra is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Testicular Cancer, Teratoma of the Mediastinum, Prostate Cancer, Orchiectomy, and Bone Marrow Transplant. Dr. Adra is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Ahmad A. Al-Hader
Oncology | Intensive Care Medicine | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Ahmad A. Al-Hader
Oncology | Intensive Care Medicine | Hematology

University Medical Diagnostic Associates Inc

535 Barnhill Dr, 
Indianapolis, IN 
 (0.1 miles away)
317-274-8660
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ahmad Al-Hader is an Oncologist and an Intensive Care Medicine provider in Indianapolis, Indiana. Dr. Al-Hader has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are ALK-Positive Non-Small Cell Lung Cancer, Squamous Cell Lung Carcinoma, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC). Dr. Al-Hader is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Greenspan's expertise for a condition
ConditionClose
    • Distinguished
    • Colorectal Cancer
      Dr. Greenspan is
      Distinguished
      . Learn about Colorectal Cancer.
      See more Colorectal Cancer experts
    • Familial Colorectal Cancer
      Dr. Greenspan is
      Distinguished
      . Learn about Familial Colorectal Cancer.
      See more Familial Colorectal Cancer experts
    • Familial Prostate Cancer
      Dr. Greenspan is
      Distinguished
      . Learn about Familial Prostate Cancer.
      See more Familial Prostate Cancer experts
    • Gastroesophageal Junction Cancer
      Dr. Greenspan is
      Distinguished
      . Learn about Gastroesophageal Junction Cancer.
      See more Gastroesophageal Junction Cancer experts
    • Large-Cell Immunoblastic Lymphoma
      Dr. Greenspan is
      Distinguished
      . Learn about Large-Cell Immunoblastic Lymphoma.
      See more Large-Cell Immunoblastic Lymphoma experts
    • Lung Cancer
      Dr. Greenspan is
      Distinguished
      . Learn about Lung Cancer.
      See more Lung Cancer experts
    View All 9 Distinguished Conditions
    • Advanced
    • Adrenal Cancer
      Dr. Greenspan is
      Advanced
      . Learn about Adrenal Cancer.
      See more Adrenal Cancer experts
    • Adrenocortical Carcinoma
      Dr. Greenspan is
      Advanced
      . Learn about Adrenocortical Carcinoma.
      See more Adrenocortical Carcinoma experts
    • Adult Immune Thrombocytopenia
      Dr. Greenspan is
      Advanced
      . Learn about Adult Immune Thrombocytopenia.
      See more Adult Immune Thrombocytopenia experts
    • Adult Soft Tissue Sarcoma
      Dr. Greenspan is
      Advanced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Agranulocytosis
      Dr. Greenspan is
      Advanced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Greenspan is
      Advanced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    View All 79 Advanced Conditions
    • Experienced
    • Acute Eosinophilic Pneumonia
      Dr. Greenspan is
      Experienced
      . Learn about Acute Eosinophilic Pneumonia.
      See more Acute Eosinophilic Pneumonia experts
    • Acute Lymphoblastic Leukemia (ALL)
      Dr. Greenspan is
      Experienced
      . Learn about Acute Lymphoblastic Leukemia (ALL).
      See more Acute Lymphoblastic Leukemia (ALL) experts
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Greenspan is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Greenspan is
      Experienced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Greenspan is
      Experienced
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    • Acute Promyelocytic Leukemia
      Dr. Greenspan is
      Experienced
      . Learn about Acute Promyelocytic Leukemia.
      See more Acute Promyelocytic Leukemia experts
    View All 148 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved